Carregant...

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual dise...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Kater, Arnon P., Kersting, Sabina, van Norden, Yvette, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H., Evers, Ludo M., Croon-de Boer, Fransien, Schreurs, John, van der Spek, Ellen, Visser, Hein, Idink, Cecile, Wittebol, Shulamiet, Hoogendoorn, Mels, Tonino, Sanne H., Mobasher, Mehrdad, Levin, Mark-David
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306887/
https://ncbi.nlm.nih.gov/pubmed/30552161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019422
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!